Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Cancer immunotherapy has entered the forefront of cancer treatment, but major challenges still exist, such as the limited proportion of patients that respond to treatment and treatment-related toxicity. Therefore, biomarkers to predict which patients will benefit from therapy without major side effe...
Main Authors: | Regina E. M. Baiden-Amissah, Sandra Tuyaerts |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/14/3586 |
Similar Items
-
The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
by: Xiangjun Liu, et al.
Published: (2021-08-01) -
Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
by: Sally Temraz, et al.
Published: (2019-08-01) -
Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome
by: Sally Temraz, et al.
Published: (2021-07-01) -
Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity
by: Veronica Lazar, et al.
Published: (2019-03-01) -
Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review
by: Chengliang Huang, et al.
Published: (2021-03-01)